Liang Ye et al.
Pakistan journal of pharmaceutical sciences, 26(2), 315-322 (2013-03-05)
Acetylcholinesterase inhibitors (AChEIs), including Huperzine A (HupA), have been the mainstay of treatment for Alzheimer's disease (AD). However, AChEIs can cause gastrointestinal side effects, which has been related to the high Cmax and short tmax after oral administration. Clinical trials